LONDON - ValiRx Plc (AIM: VAL), a biotechnology company specializing in the development of therapeutics for cancer and women's health, has announced the posting of a circular and the scheduling of a General Meeting for December 30, 2024. The notice for this meeting, which includes a Form of Proxy, was dispatched to shareholders today, following an initial announcement on December 9, 2024.
The meeting will take place at the offices of Fieldfisher LLP in London, with a focus on discussing and voting on matters that are crucial for the company's future initiatives. Details of the meeting's agenda, however, were not disclosed in the press release statement.
Shareholders are instructed to submit their proxy forms by 11:00 a.m. on December 24, 2024, to ensure their representation at the meeting. The results of the General Meeting will be announced on the same day it occurs.
Subsequent to the meeting, ValiRx has outlined a timeline for the admission and commencement of dealings in the New Ordinary Shares on the AIM market of the London Stock Exchange (LON:LSEG). If approved at the General Meeting, trading is expected to begin at 8:00 a.m. on or around December 31, 2024. Additionally, CREST accounts are anticipated to be credited with the New Ordinary Shares on the same day, with the dispatch of definitive share certificates for certificated shares to follow by January 14, 2025.
The company has indicated that the events listed in the timetable, particularly those related to the admission, placing, broker offer, and subscription, are contingent upon the passing of the resolutions at the General Meeting.
The circular is available for shareholders to review on the ValiRx website. This document will provide further details on the proposals to be discussed at the General Meeting.
ValiRx's announcement is a procedural step in the governance of the company, allowing shareholders to participate in important corporate decisions. The company has not provided additional information on the specific nature of the resolutions to be voted on at the General Meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.